Instrument Inactif

Autres langues Novavax, Inc. Nasdaq

Actions

US6700021040

Recherche biotechnologique et médicale

Autres langues

31/08	Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
28/08	Novavax, Inc., Sanofi S.A., And Takeda Pharmaceutical Company Limited Receive Approvals For XFG-Adapted Nuvaxovid Formulation In The U.S., European Union And Japan For 2026-2027 Vaccination Season
28/08	FDA genehmigt saisonale Covid-19-Impfstoffe von Biontech und anderen
28/08	FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax -- Update
28/08	Novavax's Nuvaxovid Approved in US, EU, Japan for 2026-2027 Season
28/08	Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
27/08	US FDA approves updated COVID vaccines for 2026-27 season
20/08	MORNING BRIEFING - Deutschland/Europa
19/08	US stock futures steady after tech slump; investors focus on Middle East tensions
19/08	Wall St recovers as yields ease; Moderna lifts healthcare stocks
19/08	MÄRKTE USA/Entspannung am Anleihemarkt hebt Stimmung - Kursexplosion bei Moderna
19/08	Borsa Usa rimbalza dopo calo settore tech, rendimenti in flessione, Moderna vola
19/08	Wall Street cierra en alza; acciones de Moderna se disparan
19/08	MÄRKTE USA/Sinkende Renditen beflügeln Aktien - Moderna-Kursexplosion nach Studienerfolg
19/08	Wall St up after tech selloff as yields retreat; Moderna surges
19/08	Erfolgreiche Studie zu Hautkrebs-Impfstoff beflügelt Moderna
19/08	MÄRKTE USA/Börsen behauptet erwartet - Kursexplosion bei Moderna nach Studienerfolg
06/08	Novavax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Earnings Flash (NVAX) Novavax Posts Q2 Net Loss of $0.32 a Share, vs. FactSet Est. of $0.38 Loss
06/08	Earnings Flash (NVAX) Novavax, Inc. Reports Q2 Revenue $56.7M, vs. FactSet Est of $52.5M
06/08	Novavax: Q2 Earnings Snapshot
06/08	Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
06/08	Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand
30/07	Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
29/06	Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Small Cap Comp Growth Benchmark